Gilead Faces its Greatest Threat to its Hepatitis C Drug: How Will That Impact Earnings?
February 01, 2016 at 16:12 PM EST
We are more bullish than Wall Street about Gilead, calling for EPS of $3.06 and revenue of $8.18 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.